Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

Genentech, a member of the Roche ... types of metastatic bladder or urinary tract cancer. Following a consultation with the US Food and Drug Administration (FDA), and in accordance with the ...

Highlighted by Genentech's recent US regulatory ... utilize disulphide bonds that are cleavable inside cancer cells and, once the cytotoxic drug is released, will allow for the possibility of ...

Roche Group unit Genentech said that the Food and Drug Administration approved Itovebi for treating certain breast cancer. The approval is for Itovebi in combination with palbociclib and ...

Genentech, a member of the Roche ... portfolio and clinical director of the early drug development service at Memorial Sloan Kettering Cancer Center, and one of the principal investigators of ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved ... locally advanced or metastatic breast cancer, as detected by an FDA ...

The U.S. Food and Drug Administration (FDA ... and herbal supplements. Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with ...